NURPF (Neuren Pharmaceuticals) FFO

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NURPF Neuren Pharmaceuticals Ltd NURPF
51 GF Score
Price $13.46
GF Value $5.19
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Neuren Pharmaceuticals FFO?

FFO (Funds from operations) only applies to REITs.

NURPF
51GF Score
Neuren Pharmaceuticals Ltd NURPF
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Neuren Pharmaceuticals (NURPF) Overvalued in 2026?

Based on GuruFocus' analysis, Neuren Pharmaceuticals stock appears to be overvalued. The current stock price of $13.46 is trading 159.3% above its estimated GF Value™ of $5.19. GuruFocus considers Neuren Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for NURPF:

  • FFO:
  • GF Value™: $5.19 vs. price of $13.46 (159.3% above fair value)
  • GF Score™: 51/100 with 2 warning signs

No single metric tells the full story. See the NURPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Neuren Pharmaceuticals Business Description

Other Exchanges NK9:GermanyNEU:Australia
Address 117 Camberwell Road, Suite 1.01, Hawthorn East, Melbourne, VIC, AUS, 3123
Neuren Pharmaceuticals Ltd is a biopharmaceutical company, which engages in the development of new therapies for brain injury, neurodevelopment disorders. Its drugs target symptoms resulting from acute traumatic brain injury, as well as symptoms of chronic conditions, such as Rett syndrome and Fragile X syndrome. The Group has two reportable operating segments, Commercial Products and Research and Development. It derives maximum revenue from Commercial Products.
51GF Score

Get the complete analysis for NURPF

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$13.46
Price
$5.19
GF Value